

# Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18

Susan S Chiu<sup>1,2</sup>, Mike Y W Kwan<sup>2,3</sup>, Shuo Feng<sup>4</sup>, Joshua S C Wong<sup>3</sup>, Chi-Wai Leung<sup>3</sup>, Eunice LY Chan<sup>1</sup>, J S Malik Peiris<sup>4,5</sup>, Benjamin J Cowling<sup>4</sup>

1. Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital and Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
2. These authors contributed equally to this article
3. Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong Special Administrative Region, China
4. World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
5. Center of Influenza Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China

**Correspondence:** Benjamin J Cowling (bcowling@hku.hk)

## Citation style for this article:

Chiu Susan S, Kwan Mike Y W, Feng Shuo, Wong Joshua S C, Leung Chi-Wai, Chan Eunice LY, Peiris J S Malik, Cowling Benjamin J. Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18. *Euro Surveill.* 2018;23(8):pii=18-00062. <https://doi.org/10.2807/1560-7917.ES.2018.23.8.18-00062>

Article submitted on 09 Feb 2018 / accepted on 20 Feb 2018 / published on 22 Feb 2018

**We conducted a hospital-based test-negative study in Hong Kong to estimate influenza vaccine effectiveness (VE) for the winter of 2017/18. The interim analysis included data on 1,078 children admitted between 4 December 2017 and 31 January 2018 with febrile acute respiratory illness and tested for influenza. We estimated influenza VE at 66% (95% confidence interval (CI): 43–79) overall, and 65% (95% CI: 40–80) against influenza B, the dominant virus type (predominantly B/Yamagata).**

Ongoing monitoring of influenza vaccine effectiveness (VE) provides important information to public health authorities, and supports evidence-based policy [1,2]. The test-negative study design is now used in many locations to provide timely estimates of VE [3,4]. The Hong Kong Special Administrative Region is a city with a population of 7.3 million, located on the south coast of China, and has a subtropical climate. We have been monitoring influenza VE in Hong Kong since 2009 [5-7] and present here the interim VE estimates in children for the 2017/18 winter season.

## Influenza activity in Hong Kong

Influenza circulates for most of the year in Hong Kong, with a winter peak in most years. In 2016/17, the winter influenza season was dominated by influenza A(H3N2) and had a moderate impact. That was followed by a very large summer influenza peak in July 2017 dominated by influenza A(H3N2), causing more than 400 laboratory-confirmed deaths [8]. Influenza activity had subsided through the autumn and at the end of 2017, influenza activity began to increase again, with influenza B/Yamagata predominating (Figure 1) [9]. In Hong

Kong, most influenza vaccines are administered in October and November each year. Because of the lower influenza activity and the contemporaneous administration of vaccinations in October and November, we focus in this study on the period from 4 December 2017 through 31 January 2018.


## Influenza vaccine effectiveness

We conducted our study in two large hospitals in Hong Kong, Queen Mary Hospital and Princess Margaret Hospital [7]. In each hospital we enrolled children 6 months to 17 years of age who were admitted to the general wards of these hospitals with a febrile acute respiratory illness, defined as fever of  $\geq 38^{\circ}\text{C}$  plus any respiratory symptom such as cough, runny nose or sore throat. Nasopharyngeal aspirates were obtained from all patients and tested for influenza A and B virus by direct immunofluorescence assay and reverse transcription PCR. Influenza vaccination history was recorded by research personnel in interviews with parents or legal guardians, using a standardised questionnaire, and compared with electronic medical records which contain some but not all influenza vaccinations. If parents showed any signs of being uncertain, we requested that they check their vaccination record and/or contact their private doctors if vaccination was done in the private sector.

Vaccinated children were those who had received influenza vaccination for the 2017/18 season within the 6 months before admission in a regimen and dosage appropriate for their age and influenza vaccination history. Children who needed two doses of influenza vaccination but only received one dose, or who had


**FIGURE 1**

Local influenza activity as reflected by laboratory surveillance data, Hong Kong January 2017–January 2018 (n = 6,636)



**FIGURE 2**

Timeline of recruitment of hospitalised children with acute respiratory illness who tested positive or negative for influenza virus by type/subtype, Hong Kong, 4 December 2017–31 January 2018 (n = 1,078)



**TABLE**

Comparison of hospitalised children who tested positive for influenza virus with children who tested negative for influenza, Hong Kong, 4 December 2017–31 January 2018 2018 (n = 1,078)

Characteristic	Influenza-positive (n = 339)		Influenza-negative (n = 739)		p value <sup>a</sup>	
	n	%	n	%		
Age group <sup>b</sup>	6 months–2 years	85	25.1	353	47.8	<0.001
	3–5 years	123	36.3	226	30.6	
	6–17 years	131	38.6	160	21.7	
Female		<b>158</b>	<b>46.6</b>	<b>323</b>	<b>43.7</b>	<b>0.410</b>
Receipt of influenza vaccination <sup>c</sup>						
Overall		<b>22</b>	<b>6.5</b>	<b>103</b>	<b>13.9</b>	<b>0.001</b>
By age group <sup>d</sup>	6 months–2 years	5	5.9	28	7.9	0.679
	3–5 years	9	7.3	45	19.9	0.003
	6–17 years	8	6.1	30	18.8	0.003
By type of vaccine <sup>b</sup>	Quadrivalent inactivated influenza vaccine	14	4.1	83	11.2	0.001
	Trivalent inactivated influenza vaccine	2	0.6	6	0.8	
	Both	0	0	1	0.1	
	Unknown	6	1.8	13	1.8	

<sup>a</sup> p values estimated by chi-squared tests or Fisher's exact test whenever appropriate.

<sup>b</sup> Percentages are per total positive or total negative,

<sup>c</sup> Receipt of influenza vaccination defined as receipt of a quadrivalent or trivalent inactivated influenza vaccine in an age-appropriate schedule within 6 months of hospital admission and at least 2 weeks before admission.

<sup>d</sup> Percentages are per total positive or negative within the given age group.

received vaccination within 2 weeks before hospitalisation, were categorised as unvaccinated. The 2017/18 northern hemisphere formulation of trivalent and quadrivalent inactivated influenza vaccines were used during our study period.

We used conditional logistic regression to estimate the effect of influenza vaccination in reducing the risk of influenza-associated hospitalisation in children. To account for the potential confounding of this causal effect by age, we adjusted for age and age squared in the statistical model. We matched by epidemiological week to account for potential confounding by calendar time, since vaccination uptake increases through time and the risk of influenza varies over time. Influenza VE was estimated as 1 minus the adjusted conditional odds ratio (OR), multiplied by 100% [5,6]. Statistical analyses were performed in R version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria).

From 4 December 2017 through 31 January 2018, we enrolled 1,078 hospitalised children. Of the 1,078 children, 339 (31.4%) tested positive for any influenza virus, and 271 of those 339 (79.9%) tested positive for influenza B (Figure 2). As local laboratory surveillance data indicated, almost all of the influenza B viruses circulating in Hong Kong in that period were B/Yamagata lineage viruses (Figure 1).

The characteristics of the 1,078 children are shown in the Table.

Among the children who tested negative for influenza, 103 (13.9%) had been vaccinated, while 22 (6.5%) of the children who tested positive for influenza had been vaccinated.

We estimated that influenza VE was 65.6% (95% confidence interval (CI): 42.7–79.3) overall, 66.0% (95% CI: 3.4–88.0) against influenza A and 65.3% (95% CI: 39.5–80.1) against influenza B. VE was very similar for the quadrivalent vaccine that most vaccinated children had received, and we did not have sufficient data to estimate VE precisely for children who received the trivalent vaccine.

There were 54 children younger than 8 years who had not been vaccinated in previous years and therefore required two doses of vaccine but had only received one dose at the time of admission. In our main analyses, we included these children as unvaccinated because one dose is not thought to provide full protection. In a sensitivity analysis we included these 54 children as vaccinated instead of unvaccinated, and estimated VE to be 58.1% (95% CI: 35.9–72.6) overall and 56.7% (31.4–72.7) for influenza B.

## Discussion

We found that VE against influenza B virus infections in children was moderate this winter in Hong Kong, consistent with the typical VE of inactivated vaccines against influenza B in children [10]. Our estimate was similar to the interim estimate of VE of 55% (95% CI: 38–68) against influenza B/Yamagata for the 2017/18 winter in adults in Canada where the trivalent vaccine was used [11], somewhat higher than the estimate of 41% (95% CI: 20–56) against influenza B in older children and adults in Spain again with the trivalent vaccine [12], and somewhat higher than the estimate of 42% (95% CI: 25–56) against influenza B in the United States [13]. Most vaccinated children in our study had received the quadrivalent formulation that contained a B/Yamagata component, rather than the trivalent formulation that did not. Our findings should be reassuring for northern hemisphere locations that are currently experiencing epidemics of influenza B/Yamagata, rather than the influenza A(H<sub>3</sub>N<sub>2</sub>) virus for which VE was reported to be very low [11]. In our study only 20% of influenza patients had influenza A, mostly A(H1N1)pdm09, and the estimate of VE against influenza A was less precise.

Influenza vaccination coverage in the children who tested negative for influenza is a proxy for vaccination coverage in the underlying population at risk of admission to hospital with influenza in Hong Kong, and was around 14% in this study, similar to 15% in the 2015/16 season [7], and somewhat higher than the average of 9% from 2009/10 to 2013/14 [5]. There is still considerable room for increasing the vaccination coverage in children. Since 2008, the local government has provided a subsidy for influenza vaccination administered by private-sector general practitioners to children between 6 months and 6 years of age and in October 2016, this was extended to children up to 12 years of age. The current subsidy is HKD 190 (ca EUR 20), and private general practitioners typically charge parents a consultation fee of around HKD 80–120 (EUR 8–12) in addition to collecting the subsidy. Children in low income families and children with underlying medical conditions are able to receive free vaccination from government clinics. One approach to increase vaccination coverage would be to introduce a school-based programme, and this could probably be implemented at a much lower cost per dose administered.

A limitation of our study is that we did not have lineage typing for the patients with influenza B, although local surveillance indicated that B/Yamagata was predominant. We did not have vaccine effectiveness data on adults or outpatients.

## Conclusion

We documented that influenza vaccination was associated with good protection against hospitalisation for influenza B virus infection in children 6 months to 17 years of age in Hong Kong in the winter of 2017/18.

The majority of circulating influenza B viruses were B/Yamagata lineage.

## Acknowledgements

We thank the doctors and nurses of Princess Margaret Hospital, and Ms Rose So at Queen Mary Hospital and Mr Wai Ting Hui at Princess Margaret Hospital for research support. The virological data were provided by the Public Health Laboratory Services Branch, Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region, China as part of the routine diagnostic service.

This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region (project no. 17105414 and T11-705/14N). BJC is supported by the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558). CW Leung is supported by a Mini Research Grant of Clinical Research Centre, Princess Margaret Hospital. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.

## Conflict of interest

BJC has received research funding from Sanofi and consulted for Roche. JSMP has received research funding from Crucell NV and serves as an ad hoc consultant for GlaxoSmithKline and Sanofi. The authors report no other potential conflicts of interest.

## Authors' contributions

SSC and BJC conceived the study. MYWK, JSCW and ELYC collected data. SF, ELYC and BJC analysed the data. All authors interpreted the data. BJC wrote the first draft and all authors contributed to review and revision and have seen and approved the final version.

## References

1. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. *N Engl J Med*. 2017;377(6):534–43. <https://doi.org/10.1056/NEJMoa1700153> PMID: 28792867
2. Leung VK, Cowling BJ, Feng S, Sullivan SG. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. *Euro Surveill*. 2016;21(16):30202. <https://doi.org/10.2807/1560-7917.ES.2016.21.16.30202> PMID: 27124573
3. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*. 2013;31(17):2165–8. <https://doi.org/10.1016/j.vaccine.2013.02.053> PMID: 23499601
4. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. *Expert Rev Vaccines*. 2014;13(12):1571–91. <https://doi.org/10.1586/14760584.2014.966695> PMID: 25348015
5. Cowling BJ, Chan KH, Feng S, Chan EL, Lo JY, Peiris JS, et al. The effectiveness of influenza vaccination in preventing hospitalizations in children in Hong Kong, 2009–2013. *Vaccine*. 2014;32(41):5278–84. <https://doi.org/10.1016/j.vaccine.2014.07.084> PMID: 25092636
6. Chiu SS, Feng S, Chan KH, Lo JY, Chan EL, So LY, et al. Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009–14. *Vaccine*. 2016;34(19):2164–9. <https://doi.org/10.1016/j.vaccine.2016.03.032> PMID: 27013437
7. Cowling BJ, Kwan MY, Wong JS, Feng S, Leung CW, Chan EL, et al. Interim estimates of the effectiveness of influenza vaccination against influenza-associated hospitalization in children in Hong Kong, 2015–16. *Influenza Other Respi Viruses*.

- 2017;11(1):61-5. <https://doi.org/10.1111/irv.12399> PMID: 27313064
8. Center for Health Protection Hong Kong. Local Situation of Influenza Activity (as of Aug 30, 2017). 2018;14(34). Hong Kong: Center for Health Protection; 31 Aug 2017. Available from: [https://www.chp.gov.hk/files/pdf/fluexpress\\_web\\_week34\\_31\\_8\\_2017\\_eng.pdf](https://www.chp.gov.hk/files/pdf/fluexpress_web_week34_31_8_2017_eng.pdf)
  9. Centre for Health Protection Hong Kong. Influenza virus subtyping. Hong Kong: Center for Health Protection. [Accessed: 8 Feb 2018]. Available from: <https://www.chp.gov.hk/en/statistics/data/10/641/643/2275.html>
  10. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. *Lancet Infect Dis*. 2016;16(8):942-51. [https://doi.org/10.1016/S1473-3099\(16\)00129-8](https://doi.org/10.1016/S1473-3099(16)00129-8) PMID: 27061888
  11. Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. *Euro Surveill*. 2018;23(5). <https://doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035> PMID: 29409570
  12. Castilla J, Navascués A, Casado I, Pérez-García A, Aguinaga A, Ezpeleta G, et al. Network for Influenza Surveillance in Hospitals of Navarre. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. *Euro Surveill*. 2018;23(7):18-00057.
  13. Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, et al. Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, February 2018. *MMWR Morb Mortal Wkly Rep*. 2018;67(6):180-5. <https://doi.org/10.15585/mmwr.mm6706a2> PMID: 29447141

### License and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2018.